Clinical trials: Ischemic Brain
Atherosclerosis
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated…
- Trial name
- CANTOS (NCT01327846)
- Testing
- Canakinumab, Standard of care
- Where
- 1,131 sites in United States, Argentina and 38 more
- Volunteers
- 10,066 people
- Sponsor
- Novartis Pharmaceuticals
MCA - Middle Cerebral Artery Dissection
Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
Prescription and Persistence of Antithrombotic agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients with MCA(Middle Cerebral Artery) Disease.
- Trial name
- NCT02953405
- Testing
- Clopidogrel
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Ischemic Stroke
Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
To determine the revascularization rate of the CE-marked Trevo device in large vessel occlusions in ischemic stroke patients. Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro…
- Trial name
- TREVO (NCT01088672)
- Testing
- Mechanical Thrombectomy
- Where
- 7 sites in Austria, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Stryker Neurovascular
Reperfusion Injury, Post Cardiac Arrest Brain Injury
Light Utilization COX-Inhibitory Device Therapy for Infant Cardiac Arrest (LUTICA Study). The LUCID Device is Used in the Treatment of Ischemic Brain Reperfusion Injury Caused by Cardiac Arrest in Pediatric Patients.
Approximately 15,200 children receive cardiopulmonary resuscitation (CPR) for in-hospital cardiac arrest (IHCA) each year in the United States. Of these, about 60% are less than one year of age.
- Trial name
- LUTICA (NCT07556939)
- Testing
- LUTICIA - Light Utilization COX-Inhibitory Device)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mitovation, Inc
Acute Ischemic Stroke
Thrombectomy Revascularization of Intracranial Vessel OcclusioN by Originating From Japan (TRON1-Japan)
To evaluate the efficacy and safety of catheter-based thrombectomy for reperfusion by removing a thrombus in a cerebral blood vessel in patients with acute cerebral infarction (within 8 hours after onset), in whom intravenous…
- Trial name
- TRON1-Japan (NCT02964702)
- Testing
- Thrombectomy Device T-01
- Where
- 13 sites in Japan
- Volunteers
- 50 people
- Sponsor
- JIMRO Co., Ltd.
Acute Ischemic Stroke
SY007 in Patients With Acute Ischemic Stroke
This Phase 1b multiple center, randomized, double-blind, placebo-controlled study is a dose escalation trial evaluating the safety, tolerability, PK characteristics and efficacy of SY-007 after injection in acute ischemicstroke…
- Trial name
- NCT04891913
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Atrial Fibrillation
Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)
This study will evaluate the next generation WATCHMAN Left Atrial Appendage (LAA) Closure Device as implanted in patients with non-valvular atrial fibrillation (AF) with a CHADS2 stroke risk stratification score of 1 or greater.
- Trial name
- EVOLVE (NCT01196897)
- Testing
- WATCHMAN LAA Closure Technology (Gen 4.0)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 69 people
- Sponsor
- Boston Scientific Corporation
Tachyarrhythmia, Atrial Fibrillation (AF)
Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)
This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III and BIOMONITOR IIIm that are discovered or remain even after risk analysis, risk…
- Conditions
- Tachyarrhythmia, Atrial Fibrillation (AF), Syncope, Cryptogenic Stroke
- Trial name
- NCT04025710
- Testing
- BIOMONITOR III and BIOMONITOR IIIm
- Where
- 27 sites in Australia, Austria and 4 more
- Volunteers
- 167 people
- Sponsor
- Biotronik SE & Co. KG
Stroke, Stroke, Acute
Safety Evaluation of the ReWalk ReStore Device in Subjects With Mobility Impairments Due to Stroke
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the ReWalk ReStore device in subjects with hemiplegia/hemiparesis due to ischemic or hemorrhagic stroke.
- Conditions
- Stroke, Stroke, Acute, Stroke Hemorrhagic, Hemiparesis
- Trial name
- NCT03499210
- Testing
- ReWalk ReStore device
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- ReWalk Robotics, Inc.
Ischemic Stroke
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke
The purpose of this study is to assess the safety and tolerability of allogeneic adult mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke.
- Trial name
- NCT01297413
- Testing
- Allogeneic adult mesenchymal bone marrow stem cells
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Stemedica Cell Technologies, Inc.
Ischemic Stroke
Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects
The study is designed to determine the safety, tolerability, and pharmacokinetics in healthy subjects with multiple intravenous administration of the neuroprotectant YC-6 compared to placebo.
- Trial name
- NCT03358901
- Testing
- YC-6, Vehicle
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Ischemic Stroke, Systemic Embolism
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of…
- Trial name
- LeAAPS (NCT05478304)
- Testing
- AtriClip LAA Exclusion System
- Where
- 138 sites in United States, Australia and 8 more
- Volunteers
- 6,573 people
- Sponsor
- AtriCure, Inc.
Carotid Stenosis, Atherosclerosis
Revacept in Symptomatic Carotid Stenosis
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone.
- Conditions
- Carotid Stenosis, Atherosclerosis, Stroke, Transient-ischaemic Attack
- Trial name
- RevaceptCS02 (NCT01645306)
- Testing
- Revacept
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 158 people
- Sponsor
- AdvanceCor GmbH
Stroke
Niche Trial: Navigated Inhibitory rTMS to Contralesional Hemisphere Trial
A pivotal, prospective, multi-center, randomized, controlled, double-blinded study combining active Nexstim NBS-guided 1Hz rTMS or sham-rTMS targeting the healthy hemisphere with standardized task oriented rehabilitation will be…
- Trial name
- NICHE (NCT02089464)
- Testing
- NBS-guided rTMS, Task oriented rehabilitation
- Where
- 12 sites in United States
- Volunteers
- 199 people
- Sponsor
- Nexstim Ltd
Cardiovascular Disease and Lipoprotein(a)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
- Trial name
- NCT07517263
- Testing
- Pelacarsen (TQJ230)
- Where
- 646 sites in United States, Argentina and 38 more
- Volunteers
- 5,700 people
- Sponsor
- Novartis Pharmaceuticals
Ischemic Stroke
Merci Registry - Real World Use of the Merci Retrieval System in Acute Ischemic Stroke
Post-Market Registry on Use of Merci Retrieval System. Primary data to be collected will include: Post-procedure revascularization success 90-day mRS 0-2 90-day mortality
- Trial name
- NCT00478478
- Testing
- Mechanical Thrombectomy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Stryker Neurovascular
Acute Ischemic Stroke
Safety and Efficacy of J147 in Acute Ischemic Stroke
The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients.
- Trial name
- JUMPSTART (NCT07430917)
- Testing
- J147 Emulsion for Injection
- Where
- 5 sites in United States
- Volunteers
- 196 people
- Sponsor
- Abrexa Pharmaceuticals, Inc.
Acute Ischemic Stroke
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this…
- Trial name
- PROST-2 (NCT05700591)
- Testing
- rhPro-UK, rt-PA
- Where
- 72 sites in China
- Volunteers
- 1,552 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Patent Foramen Ovale, Stroke
Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA
This study is a prospective, multicenter, randomized, controlled, single-blind, investigator-driven, non-profit clinical trial designed to compare the safety and efficacy of the Cocoon PFO Occluder with the Amplatzer PFO Occluder…
- Conditions
- Patent Foramen Ovale, Stroke, Transient Ischemic Attack (TIA)
- Trial name
- SAFE-PFO (NCT07380490)
- Testing
- PFO Closure procedure
- Where
- Germany
- Volunteers
- 1,260 people
- Sponsor
- Giuseppe Tarantini
Ischemic Symptoms, Cerebral Infarction
Pletaal SR Post Marketing Observational Study
This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this study is observational in nature to collect the safety data after administrating the Pletaal SR capsule, from baseline to 16 weeks.
- Trial name
- PLTSRPMOS (NCT01782833)
- Testing
- This is Non-interventional study
- Where
- 4 sites in South Korea
- Volunteers
- 3,635 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.